COMMUNIQUÉS West-GlobeNewswire

-
Oculis to Present at Upcoming February Investor Conferences
29/01/2024 -
KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian of Excellence Award
29/01/2024 -
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29/01/2024 -
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29/01/2024 -
Gamida Cell Actively Pursuing Strategic Alternatives
29/01/2024 -
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
29/01/2024 -
Completion of the combination between Novozymes and Chr. Hansen
29/01/2024 -
Completion of the combination between Novozymes and Chr. Hansen
29/01/2024 -
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29/01/2024 -
Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
29/01/2024 -
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29/01/2024 -
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29/01/2024 -
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29/01/2024 -
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
29/01/2024 -
Philips delivers strong full-year results; agrees with FDA on terms of consent decree focused on Philips Respironics in the US
29/01/2024 -
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
29/01/2024 -
Sirona Biochem Initiates Private Placement
27/01/2024 -
Vision Sensing Acquisition Corp. Responds to NASDAQ Letter and Hopeful of Expedient Resolution
26/01/2024 -
Daré Bioscience Announces Executive Team and Board of Directors Changes
26/01/2024
Pages